BioSpace News Archive

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 15,789,474 shares of its common stock at a price of $0.38 per share,

Rx3000® FDA certified Class II Medical device inactivates 99.97% of harmful airborne viruses & bacteria, including coronavirus strains, influenza and pneumonia

Genetic variability in cholesterol and phytosterol absorption affects cardiovascular disease risk

Three CHI Franciscan hospitals received top scores for providing quality maternity care in the region

HHS and Dept. of Defense call upon the U.S.-based CDMO to expand domestic fill/finish capacity under Operation Warp Speed.

Scientia Vascular, a leading innovator in the field of stroke treatment technology, recently received FDA clearance for its Zoom WireTM line of interventional guidewires, which are used to gain access during ischemic and hemorrhagic stroke and other challenging neurovascular and peripheral vascular procedures.

JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading, international regulatory and clinical contract research organization (CRO).

Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ, the “Company” or “HSAC 2") announced today that it closed its initial public offering of 16,000,000 ordinary shares, which included the full exercise of the underwriters’ over-allotment option.

Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute

Editas Medicine, Inc., a leading genome editing company, reported business highlights and financial results for the second quarter of 2020.